It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Extramedullary disease (EMM) represents a rare, aggressive and mostly resistant phenotype of multiple myeloma (MM). EMM is frequently associated with high-risk cytogenetics, but their complex genomic architecture is largely unexplored. We used whole-genome optical mapping (Saphyr, Bionano Genomics) to analyse the genomic architecture of CD138+ cells isolated from bone-marrow aspirates from an unselected cohort of newly diagnosed patients with EMM (n = 4) and intramedullary MM (n = 7). Large intrachromosomal rearrangements (> 5 Mbp) within chromosome 1 were detected in all EMM samples. These rearrangements, predominantly deletions with/without inversions, encompassed hundreds of genes and led to changes in the gene copy number on large regions of chromosome 1. Compared with intramedullary MM, EMM was characterised by more deletions (size range of 500 bp–50 kbp) and fewer interchromosomal translocations, and two EMM samples had copy number loss in the 17p13 region. Widespread genomic heterogeneity and novel aberrations in the high-risk IGH/IGK/IGL, 8q24 and 13q14 regions were detected in individual patients but were not specific to EMM/MM. Our pilot study revealed an association of chromosome 1 abnormalities in bone marrow myeloma cells with extramedullary progression. Optical mapping showed the potential for refining the complex genomic architecture in MM and its phenotypes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Palacky University Olomouc and University Hospital Olomouc, Department of Immunology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic (GRID:grid.10979.36) (ISNI:0000 0001 1245 3953)
2 Palacky University Olomouc and University Hospital Olomouc, Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic (GRID:grid.10979.36) (ISNI:0000 0001 1245 3953)
3 Palacky University Olomouc and University Hospital Olomouc, Department of Immunology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic (GRID:grid.10979.36) (ISNI:0000 0001 1245 3953); VŠB-Technical University of Ostrava, Department of Computer Science, Faculty of Electrical Engineering and Computer Science, Ostrava, Czech Republic (GRID:grid.440850.d) (ISNI:0000 0000 9643 2828)
4 VŠB-Technical University of Ostrava, Department of Computer Science, Faculty of Electrical Engineering and Computer Science, Ostrava, Czech Republic (GRID:grid.440850.d) (ISNI:0000 0000 9643 2828)